Invest
   Home   |   Business News   |   Personal Finance   |   World News   |   U.S. News   |   Technology   |   Stock Alert   |   Stock Picks  |   Breaking News  |   Forex  |   Gold
Custom Search

Live Nation Inc. (LYV) Has Surged To A New High On Strong Q2 Earnings

Live Nation Inc. (LYV) reported second quarter EPS of $0.29 after the bell Wednesday, up from $0.13 in the previous year. Analysts expected EPS of $0.19.

FibroGen Inc. (FGEN) Has Soared To A New High On Phase 2 Study News

FibroGen Inc. (FGEN) announced after the bell Monday that its Phase 2 study of pamrevlumab in patients with idiopathic pulmonary fibrosis met the primary efficacy endpoint.

MyoKardia Inc. (MYOK) Is Surging On Phase 2 Study Results

MyoKardia Inc. (MYOK) announced Monday morning that its Phase 2 PIONEER-HCM study of mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy patients met its primary endpoint.

Facebook Inc. (FB) Has Leaped To A New High After Strong Q2 Report

Facebook Inc. (FB) reported second quarter EPS of $1.32 after the bell Wednesday, up from $0.78 a year ago. Analysts expected EPS of $1.13.

Boeing Co. (BA) Has Surged To A New High After Guidance Increase

Boeing Co. (BA) reported second quarter core EPS of $2.55 Wednesday morning, compared to the loss of $0.44 a year ago. The consensus estimate was for EPS of $2.30.

WABCO Holdings Inc. (WBC) Has Surged To A New High On Strong Q2 Results

WABCO Holdings Inc. (WBC) reported second quarter EPS of $1.69 Thursday morning, up from $1.43 a year ago. Analysts expected EPS of $1.54. The company also increased its full year EPS forecast to between $6.05 and $6.35, from prior expectations of $5.55 to $6.05.

Scripps Networks Interactive (SNI) Is Suring On Reports Of Merger Talks

Reuters reported Wednesday morning that Scripps Networks Interactive (SNI) and Discovery Communications (DISCA) are in merger talks.

Vertex Pharmaceuticals Inc. (VRTX) Is Surging To A New High On Study Results

Vertex Pharmaceuticals Inc. (VRTX) announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis who have one F508del mutation and one minimal function mutation.
 
 
   DOW JONES
  
   NASDAQ
 
   S & P 500



 

  

 



 
 
 
   Latest News From CNN Money

Market jitters return after Barcelona attack
James Murdoch slams Trump: 'There are no good Nazis'
Top Indian tech CEO quits over 'malicious' attacks
1.8 million Chicago voter records exposed online
Trump tweets false rumor after Barcelona attack
 
 
   Latest News From The Wall Street Journal
Dow Falls 274 Points in Biggest Decline in Three Months
Cisco's Feud With Former Star Executive Turns Personal---And Costly
 
  Home
  Business News
  Personal Finance
  World News
  U.S. News
  Technology

         

               
                 Copyright , Invest.